James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.
“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”
Wall Street Journal, November 23
Read Original Post on Rutgers Today, April 28, 2026 Lt. Governor’s Daughter Blazes Her Own Trail of Service at Rutgers Ashley Caldwell, who has served on the New Brunswick school board since her junior year, graduates this spring On the first day of her final semester...
Students enrolled in Introduction to Urban Planning & Design recently took part in a hands-on field trip to two recently completed waterfront park projects as part of the course's Spring lecture series and experiential learning component. Led by Professor Carmelo...
The Bloustein School is pleased to announce that at their recent meeting, the Rutgers Board of Governors approved Will Payne and Jermaine Toney as Associate Professors with tenure. In his research, Will uses quantitative and qualitative methods to study the...
Over the last few months several Bloustein School alumni and faculty have been elected, or appointed to, key positions in New Jersey and elsewhere, underscoring the school’s longstanding role in preparing leaders who shape public policy across the state. “These...
Read Report It is my privilege to serve as the Executive Director of the New Jersey State Policy Lab. Since its launch in 2021, we have worked to build something meaningful—producing high-quality blogs and reports, sharing them widely on our website and across social...